Crispr Therapeutics Ag Earnings

Crispr Therapeutics Ag’s revenue jumped 72.53% since last year same period to $0.89Mn in the Q2 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated 3.12% jump in its revenue since last 3-months.

Crispr Therapeutics Ag’s net profit fell -64.98% since last year same period to $-208.55Mn in the Q2 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -53.35% fall in its net profits since last 3-months.

Crispr Therapeutics Ag’s net profit margin jumped 4.38% since last year same period to -23379.93% in the Q2 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -48.71% fall in its net profit margins since last 3-months.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.32 - a 5.71% jump from last quarter’s estimates.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.32.

Crispr Therapeutics Ag’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Crispr Therapeutics Ag has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.